Close Menu
Home » Regulus, Biogen Idec Ink microRNA Collaboration for Multiple Sclerosis

Regulus, Biogen Idec Ink microRNA Collaboration for Multiple Sclerosis

Aug 15, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

In exchange for its miRNA know how, Regulus will receive undisclosed upfront and milestone payments. Biogen Idec will also make an undisclosed investment in Regulus, which was formed in 2007 as a joint venture between RNAi firm Alnylam Pharmaceuticals and antisense drug developer Isis Pharmaceuticals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

RNAi Drug for Acute Hepatic Porphyria

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Hahn Hearing

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

Decade of DTC

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

Nature Studies Examine Native RNA Sequencing, Nanopore Sequencing Approach to Analyze STR Expansions

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. DiamiR Wins $492K Grant for Alzheimer's Disease Dx Research

  2. Type I CRISPR Systems Can Be Used to Edit Eukaryotic Cells

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.